- Business Wire•18 hours agoNew Data from ALXN1210 Dose-Escalation Study Presented at ASH Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexion Pharmaceuticals, Inc. announced today that new data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria showed rapid and sustained reductions in lactate dehydrogenase , a direct marker of hemolysis , in patients treated with once-monthly dosing.
- Accesswire•2 days agoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, CA / ACCESSWIRE / December 2, 2016 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") ...
- GlobeNewswire•2 days agoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALXN
NEW YORK, Dec. 02, 2016-- Pomerantz LLP announces that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. and certain of its officers. The class action, filed in United States ...
ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||122.13 x 100|
|Ask||126.25 x 100|
|Day's Range||121.39 - 123.45|
|52 Week Range||110.56 - 193.45|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||74.98|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|